Keytruda pembrolizumab: Phase Ib data

Data from 16 evaluable patients with previously untreated, unresected advanced melanoma in the open-label, international Phase Ib MASTERKEY-265 trial showed that 200 mg Keytruda pembrolizumab every 2 weeks plus Imlygic talimogene laherparepvec led to an unconfirmed ORR of 56.3%, including 2 complete responses and 7 partial responses. The disease control rate (DCR) was 68.8%. Data were presented at the Society for Melanoma Research meeting in San Francisco. ...